昌紅科技(300151.SZ):晶圓載具目前在研產品7個,多個產品進入國內主流晶圓廠的“小批量及驗證”階段
格隆匯5月7日丨昌紅科技(300151.SZ)在投資者關係表示,晶圓載具目前在研產品7個,多個產品進入國內主流晶圓廠的“小批量及驗證”階段,其中FOUP產品已獲得某國內主流晶圓廠商的採購訂單。在今年一季度已經產生數百萬收入。公司正緊鑼密鼓地加緊對人員培訓工作,爲產品大規模量產作準備,同時與國內多個晶圓廠、硅片廠保持接觸,緊密對接晶圓廠、硅片廠的各種需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.